It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Suicide attempts (SA), especially recurrent SA or serious SA, are common in substance use disorders (SUD). However, the genetic component of SA in SUD samples remains unclear. Brain-derived neurotrophic factor (BDNF) alleles and levels have been repeatedly involved in stress-related psychopathology. This investigation uses a within-cases study of BDNF and associated factors in three suicidal phenotypes (‘any’, ‘recurrent’, and ‘serious’) of outpatients seeking treatment for opiate and/or cocaine use disorder. Phenotypic characterization was ascertained using a semi-structured interview. After thorough quality control, 98 SNPs of BDNF and associated factors (the BDNF pathway) were extracted from whole-genome data, leaving 411 patients of Caucasian ancestry, who had reliable data regarding their SA history. Binary and multinomial regression with the three suicidal phenotypes were further performed to adjust for possible confounders, along with hierarchical clustering and compared to controls (N = 2504). Bayesian analyses were conducted to detect pleiotropy across the suicidal phenotypes. Among 154 (37%) ever suicide attempters, 104 (68%) reported at least one serious SA and 96 (57%) two SA or more. The median number of non-tobacco SUDs was three. The BDNF gene remained associated with lifetime SA in SNP-based (rs7934165, rs10835210) and gene-based tests within the clinical sample. rs10835210 clustered with serious SA. Bayesian analysis identified genetic correlation between ‘any’ and ‘serious’ SA regarding rs7934165. Despite limitations, ‘serious’ SA was shown to share both clinical and genetic risk factors of SA—not otherwise specified, suggesting a shared BDNF-related pathophysiology of SA in this population with multiple SUDs.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Groupe Hospitalier Saint-Louis–Lariboisière–Fernand Widal, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France (GRID:grid.50550.35) (ISNI:0000 0001 2175 4109); INSERM U1144, “Therapeutic Optimization in Neuropsychopharmacology”, Paris, France (GRID:grid.7429.8) (ISNI:0000000121866389); Université de Paris, Inserm UMR-S1144, Paris, France (GRID:grid.7429.8)
2 INSERM U1144, “Therapeutic Optimization in Neuropsychopharmacology”, Paris, France (GRID:grid.7429.8) (ISNI:0000000121866389); Université de Paris, Inserm UMR-S1144, Paris, France (GRID:grid.7429.8)
3 Groupe Hospitalier Saint-Louis–Lariboisière–Fernand Widal, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France (GRID:grid.50550.35) (ISNI:0000 0001 2175 4109); INSERM U1144, “Therapeutic Optimization in Neuropsychopharmacology”, Paris, France (GRID:grid.7429.8) (ISNI:0000000121866389); ED139, Paris Nanterre University, Nanterre, France (GRID:grid.7429.8)
4 Groupe Hospitalier Saint-Louis–Lariboisière–Fernand Widal, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France (GRID:grid.50550.35) (ISNI:0000 0001 2175 4109)
5 Université Clermont-Auvergne, Inserm UMR-1107, Neuro-Dol, Clermont-Ferrand, France (GRID:grid.494717.8) (ISNI:0000000115480420)